Aeolus initiates drug study for radiation exposure
Aeolus Pharmaceuticals has initiated a second study of its lead drug, AEOL 10150, funded by the National Institute of Allergy and Infectious Diseases radiation/nuclear medical countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract.

The study is designed to test the efficacy of AEOL 10150, as measured by survival advantage, as a treatment for damage to the GI tract due to exposure to radiation.

AEOL 10150 is a small molecule that catalytically consumes reactive oxygen and nitrogen species (free radicals), said the Mission Viejo, Calif.-based Aeolus.

Prior study showed regeneration of gastro-intestinal stem cells, reduction in severity and duration of diarrhea and improved survival in animals receiving AEOL 10150 after exposure to 15 Gy of radiation, according to Aeolus.